Skip to main content

Table 1 Characteristics of study participants (N = 35,756)

From: Association between obesity and new-onset heart failure among patients with hypertension in Thailand

Characteristics

Total

BMI < 25 kg/m2

BMI \(\geq\) 25 kg/m2

p-value

n (%)

n (%)

n (%)

Total N

35,756

18,901 (52.9)

16,855 (47.1)

 

Sex

   

 < 0.001

 Women

21,950 (61.4)

10,974 (58.1)

10,976 (65.1)

 

 Men

13,806 (38.6)

7927 (41.9)

5879 (34.9)

 

Age, years

   

 < 0.001

 Mean (SD)

64.5 (11.8)

67.8 (11.5)

60.9 (11.0)

 

 Median (Q1–Q3)

64.0 (56.0–73.0)

68.0 (60.0–76.0)

61.0 (53.0–68.0)

 

Regions

   

 < 0.001

 North

9736 (27.2)

5402 (28.6)

4334 (25.7)

 

 Central

10,057 (28.1)

5007 (26.5)

5050 (30.0)

 

 Northeast

9877 (27.6)

5285 (28.0)

4592 (27.2)

 

 South

6086 (17.0)

3207 (17.0)

2879 (17.1)

 

Location of outpatient clinics

   

 < 0.001

 Regional Hospital

2305 (6.5)

1073 (5.7)

1232 (7.3)

 

 General Hospital

5747 (16.1)

2842 (15.0)

2905 (17.2)

 

 Community Hospital

25,019 (70.0)

13,769 (72.9)

11,250 (66.8)

 

 Private Hospital

435 (1.2)

199 (1.1)

236 (1.4)

 

 Others

2250 (6.3)

1018 (5.4)

1232 (7.3)

 

Health insurance scheme

   

 < 0.001

 Universal health coverage

26,459 (74.0)

14,250 (75.4)

12,209 (72.4)

 

 Civil servant medical benefit

7107 (19.9)

3770 (20.0)

3337 (19.8)

 

 Social security

1581 (4.4)

561 (3.0)

1020 (6.1)

 

 Others

609 (1.7)

320 (1.7)

289 (1.7)

 

Smoking status

   

 < 0.001

 Never

29,048 (83.2)

14,966 (80.9)

14,082 (85.8)

 

 Ever smoker

5868 (16.8)

3531 (19.1)

2337 (14.2)

 

Alcohol use

   

 < 0.001

 Never

4118 (11.7)

2394 (12.8)

1724 (10.4)

 

 Ever alcohol use

31,226 (88.4)

16,324 (87.2)

14,902 (89.6)

 

Type 2 diabetes

   

 < 0.001

 No

30,269 (84.7)

16,433 (86.9)

13,836 (82.1)

 

 Yes

5487 (15.4)

2468 (13.1)

3019 (17.9)

 

History of ischemic heart disease

   

 < 0.001

 No

34,536 (96.6)

18,169 (96.1)

16,367 (97.1)

 

 Yes

1220 (3.4)

732 (3.9)

488 (2.9)

 

History of dyslipidemia

   

 < 0.001

 No

13,291 (37.2)

7654 (40.5)

5637 (33.4)

 

 Yes

22,465 (62.8)

11,247 (59.5)

11,218 (66.6)

 

History of renal insufficiency

   

 < 0.001

 No

31,088 (86.9)

15,863 (83.9)

15,225 (90.3)

 

 Yes

4668 (13.1)

3038 (16.1)

1630 (9.7)

 

History of ACEI/ARB use

   

 < 0.001

 No

14,008 (39.2)

8123 (43.0)

5885 (34.9)

 

 Yes

21,748 (60.8)

10,778 (57.0)

10,970 (65.1)

 

BP control for the latest two consecutive visits

   

 < 0.001

 No

17,671 (50.0)

8913 (47.8)

8758 (52.5)

 

 Yes

17,663 (50.0)

9749 (52.2)

7914 (47.5)

 

Body mass index (kg/m2)

   

 < 0.001

 Mean (SD)

25.1 (4.7)

21.7 (2.4)

28.9 (3.5)

 

 Meadina (Q1–Q3)

24.7 (22.0–27.8)

22.0 (20.1–23.6)

28.0 (26.4–30.4)

 
  1. BMI body mass index, ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, BP blood pressure, SD standard deviation